JP2005517647A5 - - Google Patents

Download PDF

Info

Publication number
JP2005517647A5
JP2005517647A5 JP2003550773A JP2003550773A JP2005517647A5 JP 2005517647 A5 JP2005517647 A5 JP 2005517647A5 JP 2003550773 A JP2003550773 A JP 2003550773A JP 2003550773 A JP2003550773 A JP 2003550773A JP 2005517647 A5 JP2005517647 A5 JP 2005517647A5
Authority
JP
Japan
Prior art keywords
use according
schizophrenia
norepinephrine reuptake
selective norepinephrine
antipsychotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003550773A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/036132 external-priority patent/WO2003049724A1/en
Publication of JP2005517647A publication Critical patent/JP2005517647A/ja
Publication of JP2005517647A5 publication Critical patent/JP2005517647A5/ja
Pending legal-status Critical Current

Links

JP2003550773A 2001-12-11 2002-11-27 ノルエピネフリン再取り込み阻害物質の認知不全処置への使用 Pending JP2005517647A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (2)

Publication Number Publication Date
JP2005517647A JP2005517647A (ja) 2005-06-16
JP2005517647A5 true JP2005517647A5 (cg-RX-API-DMAC10.html) 2006-01-26

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003550773A Pending JP2005517647A (ja) 2001-12-11 2002-11-27 ノルエピネフリン再取り込み阻害物質の認知不全処置への使用

Country Status (26)

Country Link
US (1) US20050009925A1 (cg-RX-API-DMAC10.html)
EP (1) EP1458368B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005517647A (cg-RX-API-DMAC10.html)
KR (1) KR20040066895A (cg-RX-API-DMAC10.html)
CN (1) CN1713900A (cg-RX-API-DMAC10.html)
AU (1) AU2002352625A1 (cg-RX-API-DMAC10.html)
BR (1) BR0213581A (cg-RX-API-DMAC10.html)
CA (1) CA2467802A1 (cg-RX-API-DMAC10.html)
CO (1) CO5590907A2 (cg-RX-API-DMAC10.html)
CZ (1) CZ2004709A3 (cg-RX-API-DMAC10.html)
DE (1) DE60223718T2 (cg-RX-API-DMAC10.html)
EA (1) EA200400793A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP045145A (cg-RX-API-DMAC10.html)
ES (1) ES2295435T3 (cg-RX-API-DMAC10.html)
HR (1) HRPK20040528B3 (cg-RX-API-DMAC10.html)
HU (1) HUP0402619A3 (cg-RX-API-DMAC10.html)
IL (1) IL161989A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA04005716A (cg-RX-API-DMAC10.html)
MY (1) MY136367A (cg-RX-API-DMAC10.html)
NO (1) NO20042904L (cg-RX-API-DMAC10.html)
NZ (1) NZ532065A (cg-RX-API-DMAC10.html)
PL (1) PL369311A1 (cg-RX-API-DMAC10.html)
SK (1) SK2442004A3 (cg-RX-API-DMAC10.html)
TW (1) TW200300672A (cg-RX-API-DMAC10.html)
WO (1) WO2003049724A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200404274B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
US20070105960A1 (en) * 2003-08-27 2007-05-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
US20140249180A1 (en) * 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SK4732002A3 (en) * 1999-10-13 2002-12-03 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.

Similar Documents

Publication Publication Date Title
SI1620082T1 (sl) Medicinska uporaba inhibitorjev glutaminil in glutamat ciklaz za zdravljenje Alzheimerjeve bolezniin Downovega sindroma
NZ334168A (en) Combination therapy for treatment of psychoses comprising administering an atypical antipsychotic such as olanzapine, in combination with an effective amount of a serotonin reuptake inhibitor
JP2007516193A5 (cg-RX-API-DMAC10.html)
EP1656096A4 (en) METHOD FOR REDUCING THE INFECTION RISK OF ATTACKERS
NO20041833L (no) Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet
MA28871B1 (fr) Derives tricycliques accoles pour le traitement de troubles psychotiques
EP1641748A4 (en) N-ALKYLPHENYLCARBOXAMIDE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP2063889A4 (en) SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
MXPA05013869A (es) Metabolito de quetiapina.
WO2001076599A8 (en) Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60014339T8 (de) Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
EE200100136A (et) Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
DE60113310D1 (de) Verfahren zum Abschreckgiessen zur Herstellung von Gussteilen mit eingegossenen Kanälen
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
JP2005522432A5 (cg-RX-API-DMAC10.html)
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
WO2004082584A3 (en) 5ht2c receptor antagonists in the treatment of schizophrenia
PL1828151T3 (pl) Pochodne malonoamidów jako inhibitory gama-sekretazy do leczenia choroby alzheimera
PL1631296T3 (pl) Pochodne amidu kwasu 2,3,4,5,-tetrahydrobenzo[f][1,4]oksazepino-5-karboksylowego jako inhibitory gamma-sekretazy do leczenia choroby Alzheimera
CO5590907A2 (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento de fallo cognitivo